Literature DB >> 23375847

Y chromosome loss in male patients with primary biliary cirrhosis.

Ana Lleo1, Sabine Oertelt-Prigione, Ilaria Bianchi, Lisa Caliari, Palma Finelli, Monica Miozzo, Roberta Lazzari, Annarosa Floreani, Francesca Donato, Massimo Colombo, M Eric Gershwin, Mauro Podda, Pietro Invernizzi.   

Abstract

Sex chromosome abnormalities have been advocated to be involved in the striking female prevalence of primary biliary cirrhosis (PBC) and women with PBC manifest an increased X chromosome loss in peripheral blood mononuclear cells compared to age-matched healthy women. Our knowledge of the etiopathogenesis of autoimmunity in male patients remains, however, limited. Next to the possible role of androgens and their imbalances, the Y chromosome appears as a potential candidate for influence of the immune function in men. Herein we analyzed a population of male patients with primary biliary cirrhosis (n = 26) and healthy controls (n = 88) to define a potential association of disease and the loss of the Y chromosome. We demonstrate that Y chromosome loss indeed is higher in PBC males compared to healthy controls, and this phenomenon increases with aging. We were, thus, able to confirm the existence of an analogous mechanism in the male population to previously identified X haploinsufficiency in female patients with organ-specific autoimmune disease. We propose that this commonality might represent a relevant feature in the etiopathogenesis of autoimmune diseases that should be further investigated.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23375847     DOI: 10.1016/j.jaut.2012.12.008

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  42 in total

1.  The challenge of treating orphan disease.

Authors:  Carlos Dias; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

2.  Primary biliary cirrhosis-associated hepatocellular carcinoma in Chinese patients: incidence and risk factors.

Authors:  Xue-Xiu Zhang; Li-Feng Wang; Lei Jin; Yuan-Yuan Li; Shu-Li Hao; Yan-Chao Shi; Qing-Lei Zeng; Zhi-Wei Li; Zheng Zhang; George Kk Lau; Fu-Sheng Wang
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

3.  Back to the drawing board-loss of chromosome Y (LOY) in leukocytes is associated with age-related macular degeneration.

Authors:  Lars A Forsberg
Journal:  Eur J Hum Genet       Date:  2018-10-23       Impact factor: 4.246

Review 4.  Xenobiotics and loss of tolerance in primary biliary cholangitis.

Authors:  Jinjun Wang; Guoxiang Yang; Alana Mari Dubrovsky; Jinjung Choi; Patrick S C Leung
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

5.  Unmet challenges in immune-mediated hepatobiliary diseases.

Authors:  Ulrich Beuers; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 6.  Sex-related factors in autoimmune liver diseases.

Authors:  Dorothee Schwinge; Christoph Schramm
Journal:  Semin Immunopathol       Date:  2018-10-01       Impact factor: 9.623

7.  Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.

Authors:  Angela C Cheung; Nicholas F LaRusso; Gregory J Gores; Konstantinos N Lazaridis
Journal:  Semin Liver Dis       Date:  2017-05-31       Impact factor: 6.115

Review 8.  Autoimmunity in 2013.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

Review 9.  The genetics of complex cholestatic disorders.

Authors:  Gideon M Hirschfield; Roger W Chapman; Tom H Karlsen; Frank Lammert; Konstantinos N Lazaridis; Andrew L Mason
Journal:  Gastroenterology       Date:  2013-04-10       Impact factor: 22.682

Review 10.  Proposed therapies in primary biliary cholangitis.

Authors:  Annarosa Floreani; Ying Sun; Zheng Sheng Zou; Baosen Li; Nora Cazzagon; Christopher L Bowlus; M Eric Gershwin
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2016-01-06       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.